Dr. Sanjaya Singh, who holds a Ph.D. in Molecular Biology from Banaras Hindu University and completed his postdoctoral research at the University of Texas MD Anderson Cancer Center, is a distinguished scientific leader with over 25 years of experience in the field of biotherapeutics. He is the Founder and Chief Scientific Officer of Third Arc Bio and has a proven track record of innovation across multiple therapeutic areas, including immunology, oncology, retinal, metabolic, and neurological diseases. He is a co-inventor of several breakthrough biologics, including SKYRIZI®, EBGLYSS™, PRAXBIND®, ligelizumab, and lampalizumab, many of which have received FDA breakthrough designations.

Dr. Singh previously served as Head of Janssen Biotherapeutics, where he led the global biotherapeutics discovery organization at Johnson & Johnson and defined the strategic direction for its expanding portfolio. Before that, he was Vice President of Biotherapeutics Discovery at Boehringer Ingelheim, where he successfully built and led a globally competitive preclinical and clinical pipeline. He began his industry career at Tanox Inc., heading the Biotherapeutics division until the company’s acquisition by Genentech.

In addition to his executive leadership roles, Dr. Singh co-founded Aliada Therapeutics, a neuroscience and blood-brain barrier platform company recently acquired by AbbVie, and currently serves as a Venture Partner at Omega Funds, a leading life sciences investment firm. He has authored numerous peer-reviewed publications and holds over 60 patents, with significant contributions spanning basic research, platform technologies, and therapeutic biologics.

At Syngene, Dr. Singh contributes his extensive scientific and strategic expertise as a member of the Nomination & Remuneration Committee, the Science & Technology Committee, and the Corporate Social Responsibility Committee.